No Data
No Data
Shanghai Bio-heart Biological Technology Shrinks H1 Loss
Bai Xin An -B (02185) announced its interim performance. The loss attributable to the parent company's owners was 25.83 million yuan, with a year-on-year narrowing of 70%.
Baixinan-B (02185) announced its mid-term performance in 2024, with R&D spending of approximately RMB 21.8 million (adjusted for inflation). ...
Express News | Shanghai Bio-Heart Biological Technology H1 Net Income RMB -28.3 Million
Express News | Shanghai Bio-Heart Biological Technology H1 Capex RMB 19.8 Million
Express News | Shanghai Bio-Heart Biological Technology H1 EPS RMB -0.11
BIOHEART-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
No Data
No Data